18756942

Source:http://linkedlifedata.com/resource/pubmed/id/18756942

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0023413, umls-concept:C0036525, umls-concept:C0123931, umls-concept:C0205132, umls-concept:C0205269, umls-concept:C1522484, umls-concept:C1527249
pubmed:issue	3
pubmed:dateCreated	2008-9-1
pubmed:abstractText	Irinotecan (CPT-11), a specific inhibitor of topoisomerase I, has been proven to be effective in the treatment of refractory or metastatic colorectal cancer. Furthermore, several first line phase III trials of the combination therapy (FOLFIRI) using CPT-11 and fuorouracil/leucovorin (5-Fu/LV) were reported to have significant improvement in treatment result. Therefore, we designed a multicenter clinical study to observe the overall survival (OS), time to death (TTD), time to progression (TTP), efficacy and safety of FOLFIRI regimen for patients with refractory or metastatic colorectal cancer after first line chemotherapy failure.
pubmed:language	chi
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7910681
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	0253-3766
pubmed:author	pubmed-author:ChuFF, pubmed-author:ChuYu-PingYP, pubmed-author:JinMao-LinML, pubmed-author:LiJianJ, pubmed-author:LiuDuan-QiDQ, pubmed-author:LoyMM, pubmed-author:ShenLinL, pubmed-author:WangYong-HuaYH, pubmed-author:XuJian-MingJM, pubmed-author:ZhangXiao-DongXD
pubmed:issnType	Print
pubmed:volume	30
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	225-7
pubmed:meshHeading	pubmed-meshheading:18756942-Adult, pubmed-meshheading:18756942-Aged, pubmed-meshheading:18756942-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18756942-Camptothecin, pubmed-meshheading:18756942-Colonic Neoplasms, pubmed-meshheading:18756942-Disease Progression, pubmed-meshheading:18756942-Female, pubmed-meshheading:18756942-Fluorouracil, pubmed-meshheading:18756942-Follow-Up Studies, pubmed-meshheading:18756942-Humans, pubmed-meshheading:18756942-Leucovorin, pubmed-meshheading:18756942-Male, pubmed-meshheading:18756942-Middle Aged, pubmed-meshheading:18756942-Neoplasm Metastasis, pubmed-meshheading:18756942-Neoplasm Recurrence, Local, pubmed-meshheading:18756942-Neutropenia, pubmed-meshheading:18756942-Prospective Studies, pubmed-meshheading:18756942-Rectal Neoplasms, pubmed-meshheading:18756942-Remission Induction, pubmed-meshheading:18756942-Survival Rate, pubmed-meshheading:18756942-Vomiting, pubmed-meshheading:18756942-Young Adult
pubmed:year	2008
pubmed:articleTitle	[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
pubmed:affiliation	Department of Gastrointestinal Medical Oncology, Beijing University School of Oncology, Beijing 100036, China.
pubmed:publicationType	Journal Article, Clinical Trial, English Abstract, Multicenter Study